Myokardia at inflection point as heart drug readout nears

Results are due soon from EXPLORER, Myokardia's first-ever Phase 3 study and a major test of the company's heart disease treatment mavacamten.

Myokardia at inflection point as heart drug readout nears
Results are due soon from EXPLORER, Myokardia's first-ever Phase 3 study and a major test of the company's heart disease treatment mavacamten.